eViralHepatitis Review
Volume 4, Issue 8, Part 3
Sofosbuvir/Velpatasvir fixed dose combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study
Sofosbuvir/Velpatasvir fixed dose combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study